Keytruda shows consistent efficacy and safety in advanced bladder carcinoma patients ineligible for platinum-based chemotherapy, with varying objective response rates and survival metrics across ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s MRK Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, ...

Moderna and Merck said their experimental vaccine in combination with the therapy Keytruda improved survival and showed durable efficacy in a midstage study in patients with a deadly form of skin ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the treatment of bladder cancer. The PD-1/antibody-drug conjugate pairing ...

Friday, Merck & Co Inc (NYSE:MRK) announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, of Keytruda (pembrolizumab) in combination with chemoradiotherapy (CRT) met its ...

For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.

TOKYO and NEW YORK, Oct. 18, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive results from the ...